个人简历

2003年回国后被中山大学肿瘤防治中心聘为副研究员，组建肿瘤病毒学和肿瘤分子标志研究组；2006年聘为研究员，博士生导师，入选2006年“教育部新世纪优秀人才计划”； 并获得2010年“国家杰出青年科学基金”项目资助，2014年被聘为教育部“长江学者”特聘教授；2016年入选广东省培养高层次人才特殊支持计划“杰出人才”（南粤百杰）。现任中山大学肿瘤防治中心副主任、副院长，中国抗癌协会理事，广东省抗癌协会第四届理事会常务理事、秘书长，中国抗癌协会肿瘤标志专业委员会副主任委员，广东省抗癌协会转移委员会主任委员。 【教育背景】 1988年毕业于江西医学院抚州分院（现南昌大学抚州医学分院） 1994年毕业于中山大学（原中山医科大学），获肿瘤学硕士学位 1998年毕业于中山大学（原中山医科大学），获微生物学博士学位。【留学经历】 1999-2000年美国田纳西州立大学生物系（Tennessee State University）博士后，从事维甲酸在细胞发育及分化中作用的研究 2000-2003年美国波士顿塔夫茨大学—新英格兰医学中心(Tufts University-New England Medical Center)肿瘤生物学实验室从事乳腺癌发病机理、诊断及预后指标的研究。

研究领域

1. 肿瘤病毒感染、致癌及免疫调控机制 2. 恶性肿瘤分子标志及早期诊断 3. 分子影像及靶向治疗

近期论文

1）Zhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, Dong XD, Li SB, Du Y, Xiong D, He JY, Li MZ, Liu YM, Zhou AJ, Zhong Q, Zeng YX, Kieff E, Zhang ZQ, Gewurz BE, Zhao B*, Zeng MS*, Ephrin receptor A2 is an epithelial cell receptor for EBV entry. Nat Microbiol, 2017. (In Press) 2）Zhong Q, Liu Z, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X*, Zeng MS*, The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res, 2017. 3）Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS*, Zhang Z*, TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun, 2017. 8(1): p. 945 4）Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, Xia TL, Li RY, Zhou AJ, Su Z, Huang YH, Huang QT, Huang LY, Zhang X, Zhao YN, Yun JP, Wu QL, Lin DX, Bai F*, Zeng MS*, Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun, 2017. 8(1): p. 524. 5）Tang LQ, Zhang H, Li Y, Zhang A, Chen ML, Li SB, Mai HQ*, Zeng MS*, A Sponsored Supplement to Science：Precision medicine in China，Chapter 2， Precision medicine for nasopharyngeal carcinoma， Science, 2016.12.23, 24~27 6）Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, Wang HY, Xie D, Claret FX, Song EW, Zeng MS*, RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis, 2016. 7(9): p. e2352 7）Hu LJ, Lin ZR, Wu YH, Dong JQ, Zhao B, Cheng YB, Huang PY, Xu LH, Xia TL, Xiong D, Wang HB, Li MZ, Guo L, Kieff E, Zeng YX, Zhong Q*, Zeng MS*, Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med, 2016. 10(1): p. 61-75. 8）Li RC, Du Y, Zeng QY, Tang LQ, Zhang H, Li Y, Liu WL, Zhong Q, Zeng MS*, Huang XM*, Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma. Clin Lab, 2016. 62(4): p. 553-61. 9）Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ*, Zeng MS*, Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst, 2016. 108(1). 10）Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q*, Zeng MS*, Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis, 2015. 6: p. e1920. 11）Xiong D, Du Y, Wang HB, Zhao B, Zhang H, Li Y, Hu LJ, Cao JY, Zhong Q, Liu WL, Li MZ, Zhu XF, Tsao SW, Hutt-Fletcher LM, Song E, Zeng YX, Kieff E*, Zeng MS*, Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A, 2015. 112(35): p. 11036-41. 12）Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, Du Y, Xiong D, Zhong Q, Liu WL, Du H, Li MZ, Huang WL, Tsao SW, Hutt-Fletcher L, Zeng YX, Kieff E, Zeng MS*, Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun, 2015. 6: p. 6240. 13）Tang LQ, Hu DP, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Wen SH, Peng YT, Chen WH, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS*, Mai HQ*, Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. PLoS One, 2015. 10(4): p. e0122965. 14）Ni C, Chen Y, Zeng M (co-first author), Pei R, Du Y, Tang L, Wang M, Hu Y, Zhu H, He M, Wei X, Wang S, Ning X, Wang M, Wang J, Ma L, Chen X, Sun Q, Tang H, Wang Y, Wang X*, In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res, 2015. 25(7): p. 785-800. 15）Zong D, Yin L, Zhong Q, Guo WJ, Xu JH, Jiang N, Lin ZR, Li MZ, Han P, Xu L, He X*, Zeng MS*. ZNF 488 Enhances the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma via the Wnt Signaling Pathway Involving Epithelial Mesenchymal Transition. Cancer Res Treat. 2015 Mar 12. doi: 10.4143/crt.2014.311. 16）Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM*, Zeng MS*, Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma. Mol Med Rep, 2015. 12(1): p. 401-9. 17）Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Chen WH, Liu H, Guo SS, Liu LT, Li J, Zhang JP, Guo L, Zhao C, Cao KJ, Qian CN, Zeng YX, Guo X, Mai HQ*, Zeng MS*, High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys, 2015. 91(2): p. 325-36. 18）Feng GK, Liu RB, Zhang MQ, Ye XX, Zhong Q, Xia YF, Li MZ, Wang J, Song EW, Zhang X*, Wu ZZ*, Zeng MS*, SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide. J Control Release, 2014. 192: p. 236-42.